$0.34
7.73%
Nasdaq, Sep 02, 10:11 pm CET
ISIN
US1850631045
Symbol
CLSD

Clearside Biomedical, Inc. Stock price

$0.34
-0.08 18.31% 1M
-0.45 57.21% 6M
-0.61 64.31% YTD
-0.67 66.43% 1Y
-1.02 75.07% 3Y
-1.30 79.32% 5Y
-6.91 95.32% 10Y
-6.91 95.32% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.03 7.73%
ISIN
US1850631045
Symbol
CLSD
Industry

Key metrics

Basic
Market capitalization
$26.6m
Enterprise Value
$17.2m
Net debt
positive
Cash
$9.4m
Shares outstanding
78.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.4 | 8.1
EV/Sales
4.1 | 5.2
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-154.6%
Return on Equity
88.4%
ROCE
-178.0%
ROIC
-541.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$4.2m | $3.3m
EBITDA
$-21.5m | $-17.7m
EBIT
$-21.9m | $-24.8m
Net Income
$-27.7m | $-17.2m
Free Cash Flow
$-22.2m
Growth (TTM | estimate)
Revenue
-44.6% | 98.7%
EBITDA
16.1% | 38.4%
EBIT
15.2% | 14.2%
Net Income
17.2% | 49.9%
Free Cash Flow
-10.3%
Margin (TTM | estimate)
Gross
90.5%
EBITDA
-516.9% | -535.3%
EBIT
-524.6%
Net
-665.2% | -522.0%
Free Cash Flow
-533.7%
More
EPS
$-0.4
FCF per Share
$-0.3
Short interest
2.3%
Employees
32
Rev per Employee
$50.0k
Show more

Is Clearside Biomedical, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Clearside Biomedical, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Clearside Biomedical, Inc. forecast:

7x Buy
54%
6x Hold
46%

Analyst Opinions

13 Analysts have issued a Clearside Biomedical, Inc. forecast:

Buy
54%
Hold
46%

Financial data from Clearside Biomedical, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4.17 4.17
45% 45%
100%
- Direct Costs 0.40 0.40
186% 186%
10%
3.77 3.77
47% 47%
90%
- Selling and Administrative Expenses 11 11
2% 2%
269%
- Research and Development Expense 14 14
33% 33%
346%
-22 -22
16% 16%
-516%
- Depreciation and Amortization 0.32 0.32
191% 191%
8%
EBIT (Operating Income) EBIT -22 -22
15% 15%
-524%
Net Profit -28 -28
17% 17%
-665%

In millions USD.

Don't miss a Thing! We will send you all news about Clearside Biomedical, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Clearside Biomedical, Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
- Presentations Highlight the Versatility of Clearside's SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases -
Neutral
GlobeNewsWire
about one month ago
- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside's Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the e...
Neutral
GlobeNewsWire
about 2 months ago
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases -
More Clearside Biomedical, Inc. News

Company Profile

Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Head office United States
CEO George Lasezkay
Employees 32
Founded 2011
Website clearsidebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today